June 13, 2019: Integrated stepped alcohol treatment in HIV clinics; cytokines, inflammation, and heart risk; impact of CCR5 gene editing on lifespan; the costs of "test and treat" for hepatitis C.
Two models, one from Washington State and another from Los Angeles County, can be duplicated elsewhere to get people into care, experts say.
It is estimated that one-third of Americans with hepatitis C pass through the criminal justice system each year.
Post-incarceration HIV outcomes worse among women; no drug resistance despite apparent PrEP failure; cost-efficacy of adherence self-management; additional cancers in HIV-positive cancer survivors.
HIV-positive donor, HIV-negative recipient; continuum of care after incarceration in U.S.; reduced bone mineral density among men with HIV under 50; discouraging anti-inflammatory findings for an antiplatelet agent.
A survey of 49 states reveals that an estimated 144,000 inmates with hepatitis C can't get the expensive drugs they need to cure it.
The recent approval of a less expensive drug that generally cures hepatitis C in just eight weeks may make it easier for more insurers and correctional facilities to expand treatment.
"Like it or not, if we are ever going to eliminate hepatitis C, we are going to have to test and treat prisoners," Alan Franciscus writes.
"Jail and prison officials often say the high cost of HCV management and treatment forces them to create guidelines so those with the greatest degree disease progression get care first," Matthew Zielske writes. "Such actions lead to rationing which r...
A study of state departments of correction concludes that prisoners are not receiving vital hepatitis C treatment due to extremely high drug costs.